Oncology Letters最新文献

{"title":"Diagnostic and therapeutic challenges of locally advanced colon cancer complicated with acute lymphoblastic leukemia: A case report.","authors":"Yuping Zeng, Song Mu, Guosheng Li, Zhengzi Liang, Qinghua Ji, Yunhuan Zhen, Wenling Wang, Weiwei Chen","doi":"10.3892/ol.2026.15627","DOIUrl":"10.3892/ol.2026.15627","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is the second most common malignant tumor in China, characterized by a steadily increasing annual incidence. Acute lymphoblastic leukemia (ALL) is a malignant clonal disorder originating from lymphoid progenitor cells that predominantly affects children and adolescents. Its incidence is relatively lower in adults than in children, however they typically experience poorer prognoses. Although CRC and ALL each have distinct pathological and epidemiological profiles, their coexistence as synchronous or metachronous double primary malignancies in the same patient is rare and their treatment strategies differ. The current study presents a case of locally advanced colon cancer concurrent with ALL, in which the patient underwent radical colon cancer surgery after achieving complete remission of ALL through induction chemotherapy.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"32 1","pages":"273"},"PeriodicalIF":2.1,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13169109/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147942484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary thyroid lymphoma with Hashimoto's thyroiditis: A case report and literature review.","authors":"Fangshu Liu, Xueya Xin, Kai Tan, Xinv Chen, Chanjuan Shen, Qiuhong Yang","doi":"10.3892/ol.2026.15625","DOIUrl":"10.3892/ol.2026.15625","url":null,"abstract":"<p><p>Primary thyroid diffuse large B-cell lymphoma (DLBCL) represents a rare and diagnostically challenging malignancy, particularly when arising in the setting of pre-existing Hashimoto's thyroiditis (HT). The present case report describes the case of an 86-year-old female patient with primary thyroid lymphoma (PTL) who presented with life-threatening tracheal compression. The aim of this report is to emphasize the diagnostic challenges due to overlapping clinical features with thyroid carcinoma and the absence of consensus management guidelines. Following ultrasound-guided biopsy and immunohistochemical analysis, germinal center-originated DLBCL was confirmed. The patient received four cycles of zuberitamab (a novel anti-CD20 monoclonal antibody) plus mini-CHOP therapy, with CT imaging demonstrating notable tracheal re-expansion after the first cycle. Successful disease control and quality of life were maintained throughout the follow-up. Furthermore, a comprehensive literature review was performed to elucidate the clinical manifestations and therapeutic approaches of PTL. In conclusion, the present case exemplifies that elderly patients with rapidly enlarging neck masses require urgent evaluation to distinguish between thyroid lymphoma and carcinoma. While individual case results cannot be generalized to all clinical scenarios, prompt diagnosis followed by appropriate treatment remains critical for favorable outcomes.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"32 1","pages":"270"},"PeriodicalIF":2.1,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13169117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147942046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A clear cell sarcoma tumor of the finger with an unusual presentation misdiagnosed as a glomus tumor in an adolescent patient: A case report.","authors":"Abdulrahman Alaseem, Hatim Khoja, Khalid Murrad, Sarah Alkhalife, Nouf Altwaijri, Abdullah Almawi, Abdulaziz Bin Dakhil, Abdulaziz Alhammad, Banan Alqady, Eman Najjar","doi":"10.3892/ol.2026.15626","DOIUrl":"10.3892/ol.2026.15626","url":null,"abstract":"<p><p>Clear cell sarcoma (CCS) is an uncommon malignancy originating from neural crest cells; this type of cancer can mimic a number of other tumors and frequently presents in the lower limbs, but is occasionally found in atypical locations. The present study describes a rare case of a 14-year-old girl presenting with a subungual swelling on the right index finger, with the initial impression of a glomus tumor, who underwent unplanned surgical resection at another institution. The histopathological analysis revealed CCS with positive margins, and the patient was therefore referred to an orthopedic oncology specialist King Khalid University Hospital (King Saud University Medical City, Riyadh, Saudi Arabia), for further management. Local and systemic staging workups confirmed localized disease; hence, local control was achieved by amputation at the base of the middle phalanx level, with negative margins achieved without chemotherapy or radiation therapy. Finger tumors may impose diagnostic challenges due to their rarity and similarity with more common benign conditions. A high index of suspicion is important to make an early, accurate diagnosis, and to avoid inappropriate management and poor outcomes. The current case is one of the few published reports of CCS arising in the finger and, to the best of our knowledge, the second pediatric case. Therefore, the present study contributes to the limited literature on CCS presenting in an unusual location such as the hand, with the aim of avoiding errors in diagnosis and management.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"32 1","pages":"271"},"PeriodicalIF":2.1,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13169118/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147942442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Watch-and-wait in rectal cancer: A critical appraisal of promise, perils and unresolved contours of organ preservation (Review).","authors":"Xinqiang Zhu, Beibei Ge, Linchun Wen, Siwei Shan","doi":"10.3892/ol.2026.15631","DOIUrl":"10.3892/ol.2026.15631","url":null,"abstract":"<p><p>Total neoadjuvant therapy has elevated pathological complete response (pCR) rates in locally advanced rectal cancer to unprecedented levels (25-30%), catalyzing interest in organ preservation via the non-surgical 'Watch-and -Wait' (WaW) strategy. Although this approach offers a paradigm shift, its rapid clinical adoption necessitates a critical appraisal of unresolved controversies. The present review synthesizes current evidence to outline the benefits of WaW while critically examining its inherent challenges. A comprehensive analysis interrogates the dualistic nature of WaW. It can provide favorable survival (5-year overall survival of 85% and cancer-specific survival of 94% in the International WaW Database) and meaningful quality-of-life improvements by avoiding radical surgery; concurrently, it embodies substantial risks due to the inherent imprecision of clinical complete response (cCR) assessment (a 10-25% discordance with pCR), a marked local regrowth rate (~25%) and unresolved long-term oncological uncertainties. In the present review it is argued that successful implementation of WaW depends on transcending current limitations through technological integration. Circulating tumor DNA is a promising but still investigational biomarker that may enable dynamic risk stratification; however, its clinical utility requires prospective validation. In conclusion, WaW has evolved from a radical concept to a reasonable, evidence-supported option within a precision oncology framework for a meticulously selected patient cohort, contingent upon rigorous multidisciplinary team assessment and an unwavering, structured surveillance protocol. Its future safety and efficacy will be defined by advances in response assessment, personalized monitoring and long-term outcome data.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"32 1","pages":"276"},"PeriodicalIF":2.1,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13169478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147942136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LINC00184 promotes esophageal squamous cell carcinoma progression via DNMT1-mediated methylation of the NDRG2 promoter and PI3K/AKT pathway activation.","authors":"Junjun Guo, Shenbo Fu, Jia Liu, Lina Li, Jin Zhao, Fenggang Wang, Wenan Wu, Xu Chen, Enxiao Li","doi":"10.3892/ol.2026.15628","DOIUrl":"10.3892/ol.2026.15628","url":null,"abstract":"<p><p>Esophageal squamous cell carcinoma (ESCC) is a highly aggressive cancer with poor clinical outcomes, highlighting the need for enhanced understanding of its molecular drivers. The present study investigated the functional role of long non-coding RNA LINC00184 in ESCC progression. Using overexpression experiments in KYSE-150 and TE-1 cell lines, the present study demonstrated that LINC00184 significantly enhances ESCC cell proliferation and migration while inhibiting apoptosis. Mechanistic studies revealed that LINC00184 recruits DNA methyltransferase 1 (DNMT1) to the promoter of the tumor suppressor gene N-Myc downstream regulated gene 2 (NDRG2), thereby catalyzing CpG island hypermethylation and transcriptional silencing of NDRG2. The subsequent downregulation of NDRG2 results in activation of the oncogenic PI3K/AKT signaling pathway. Notably, treatment with the DNMT1 inhibitor 5-azacytidine reverses LINC00184-induced NDRG2 promoter methylation, restores NDRG2 expression and attenuates PI3K/AKT pathway activation. The present study findings identified a novel LINC00184/DNMT1/NDRG2/PI3K-AKT regulatory axis in ESCC and suggested that targeting this epigenetic pathway may represent a promising therapeutic strategy in the future.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"32 1","pages":"272"},"PeriodicalIF":2.1,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13169231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147941383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SOX2-positive upper tract urothelial carcinoma: Clinicopathological characteristics and therapeutic implications.","authors":"Hitomi Yasukawa, Yoshinori Ikehata, Naotaka Nishiyama, Hiroshi Kitamura","doi":"10.3892/ol.2026.15629","DOIUrl":"10.3892/ol.2026.15629","url":null,"abstract":"<p><p>Upper tract urothelial carcinoma (UTUC) is a rare subtype of urothelial malignancy associated with poor prognosis, particularly in advanced stages. Sex determining region-Y-related high mobility group box 2 (SOX2), a key transcription factor involved in the maintenance of cellular stemness, has been identified as a potential biomarker in multiple cancer types; however, its prognostic significance in UTUC remains unclear. The present study aimed to investigate the expression pattern of SOX2 in UTUC and examine its association with clinicopathological characteristics. Moreover, the present study aimed to evaluate the association of SOX2 with programmed cell death ligand 1 (PD-L1) and antibody-drug conjugate (ADC) targets, including Nectin-4 and trophoblast cell surface antigen 2, to explore potential therapeutic implications. A total of 87 patients with UTUC who underwent radical nephroureterectomy were retrospectively analyzed. SOX2 expression was assessed using immunohistochemistry with a 10% cut-off value. Notably, SOX2 expression was detected in 24% (21/87) of cases. No significant associations were observed between SOX2 expression and clinicopathological parameters, molecular subtypes, or the expression of PD-L1 and ADC targets, except for hydronephrosis grade. Patients with SOX2-positive tumors exhibited significantly worse overall survival (OS), cancer-specific survival (CSS) and recurrence-free survival (RFS; P=0.004, P=0.005 and P=0.011, respectively) during a median follow-up period of 39.3 months. The 5-year CSS rates were 69% in the SOX2-negative group and 43% in the SOX2-positive group. Multivariate analysis identified SOX2 expression as an independent prognostic factor for CSS (P=0.001). Among patients who did not receive perioperative chemotherapy, those with SOX2-positive tumors demonstrated significantly poorer OS, CSS and RFS, compared with SOX2-negative patients. These findings indicated that SOX2 expression represents an independent and robust prognostic biomarker in UTUC, identifying a biologically distinct high-risk subgroup with unfavorable clinical outcomes. The preserved expression of PD-L1 and ADC targets in this subgroup may suggest potential responsiveness to immune checkpoint inhibitors and ADC-based therapies, supporting the consideration of intensified perioperative or systemic treatment strategies in SOX2-positive patients.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"32 1","pages":"274"},"PeriodicalIF":2.1,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13169476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147942119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-omics profiling of pancreatic neuroendocrine tumors: Interplay of genomic instability and the tumor microenvironment (Review).","authors":"Yin Wan, Yingnan Zhang, Philip A Philip, Herbert Chen, Bassel El-Rayes, Asfar S Azmi, Yang Shi","doi":"10.3892/ol.2026.15630","DOIUrl":"10.3892/ol.2026.15630","url":null,"abstract":"<p><p>Pancreatic neuroendocrine tumors (PNETs) represent a biologically heterogeneous group of neoplasms shaped by both intrinsic genomic alterations and dynamic interactions with the tumor microenvironment (TME). Conventional analytical approaches offered limited insight into these complex mechanisms. However, the emergence of multi-omics technologies including genomics, transcriptomics, proteomics and spatial single-cell platforms dramatically expanded current understanding of tumor evolution, immune-stromal crosstalk and phenotypic plasticity. In the present review, findings from novel multi-omics studies were integrated to reframe PNET biology through the perspective of TME co-evolution. The present review highlighted how genomic instability serves as a key driver, promoting transcriptomic reprogramming and clonal evolution that subsequently remodels the TME into an immunosuppressive niche rich in cancer-associated fibroblasts and characterized by immune exclusion. The present review further emphasized the novel role of spatial multi-omics in deciphering the spatial heterogeneity of the PNET ecosystem. These insights accelerated the identification of novel biomarkers and revealed novel therapeutic susceptibilities, potentially paving the way for rational combination strategies that target both tumor-intrinsic pathways and microenvironmental constraints. Therefore, the present review proposed that multi-omics profiling provides not only a descriptive landscape but a mechanistic framework for precision oncology, enabling improved patient stratification and biomarker-driven therapeutic interventions in PNETs.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"32 1","pages":"275"},"PeriodicalIF":2.1,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13169482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147941939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploration of the effect and mechanism of <i>Eclipta prostrata L.</i> against gastric cancer based on network pharmacology and experimental verification.","authors":"Weizhou Yu, Xiaohui Ni, Jing Wang, Wei Xia, Xinya Shen, Fan Qiu, Yuping Chen","doi":"10.3892/ol.2026.15620","DOIUrl":"10.3892/ol.2026.15620","url":null,"abstract":"<p><p>The present study aimed to explore the therapeutic effects and underlying mechanisms of the active constituents of <i>Eclipta prostrata L</i>. in gastric cancer (GC) and to identify potential targets for its prevention and treatment. Active compounds and their corresponding targets were screened using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform. In comparison, GC-related targets were retrieved from GeneCards and Online Mendelian Inheritance in Man databases. Common targets were identified using Venny 2.1.0. Cytoscape 3.10.2 was then employed to construct a traditional Chinese medicine component-target-disease network and a protein-protein interaction network. Core compounds and targets were further assessed through molecular docking, and the potential mechanisms were investigated using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses. The biological activity of luteolin, the principal active component of <i>Eclipta prostrata L</i>., was experimentally validated in AGS cells using Cell Counting Kit-8 assays, wound-healing (scratch) assays, Transwell migration assays, flow cytometry and western blotting. A total of 10 active ingredients and 166 shared targets were identified. Among them, quercetin, luteolin and acacetin were identified as key bioactive constituents, whereas AKT serine/threonine kinase 1 (AKT1), TNF and hypoxia-inducible factor-1 (HIF-1A) were recognized as central targets. Molecular docking analysis revealed strong binding affinities between the core compounds and these targets. Enrichment analyses further indicated that the therapeutic effects of <i>Eclipta prostrata L</i>. may involve pathways related to oxidative stress, the phosphatidylinositol 3-kinase-protein kinase B signaling pathway, and the HIF-1 signaling pathway. Among the identified compounds, luteolin showed the most pronounced inhibitory effects on GC cells and was therefore selected for further mechanistic investigation. <i>In vitro</i> experiments demonstrated that luteolin significantly suppressed GC cell proliferation and migration, reduced AKT phosphorylation and HIF-1A expression, and did not induce apoptosis. These findings suggest that luteolin may exert its anti-GC effects primarily by modulating the AKT1/HIF-1A signaling axis. The present study provides experimental support for the therapeutic potential of <i>Eclipta prostrata L.</i>-derived compounds and offers insights into novel molecular targets for GC treatment.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"31 6","pages":"265"},"PeriodicalIF":2.1,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13139816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147841067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in cerebrospinal fluid biomarkers for the diagnosis, treatment and monitoring of leptomeningeal metastases (Review).","authors":"Huaixu Li, Wenwen Fan, Fengchun Mu, Cheng Fang, Ting Xiao, Jinghai Wan, Hongqing Cai","doi":"10.3892/ol.2026.15621","DOIUrl":"10.3892/ol.2026.15621","url":null,"abstract":"<p><p>Leptomeningeal metastasis (LM) is an aggressive complication characterized by the dissemination of malignant cells to the leptomeninges, typically resulting in rapid neurological deterioration and poor prognosis. Clinical diagnosis and management are impeded by non-specific symptoms and the limited sensitivity of conventional cerebrospinal fluid (CSF) cytology. Consequently, CSF biomarkers have emerged as critical tools for diagnosis, treatment monitoring and prognostic evaluation. The present review summarizes recent advancements in CSF biomarkers, categorizing them into proteins, nucleic acids and metabolites. These biomarkers enhance diagnostic accuracy, facilitate longitudinal disease tracking and assess therapeutic efficacy. Despite notable progress, challenges persist regarding biomarker sensitivity, specificity and standardization. Furthermore, the potential of multi-omics technologies and single-cell analysis is discussed as a pathway for discovering novel biomarkers to enable the precise stratification and personalized management of LM.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"31 6","pages":"266"},"PeriodicalIF":2.1,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13139829/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147841119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the mechanism of action of glaucocalyxin D against acute myeloid leukemia using network pharmacology, molecular docking and cellular experiments.","authors":"Lian Chen, Weixian Yang, Weiqing Zhang, Heng Luo, Chen Yan","doi":"10.3892/ol.2026.15622","DOIUrl":"10.3892/ol.2026.15622","url":null,"abstract":"<p><p>Glaucocalyxin D (GLD), an ent-kaurane diterpenoid isolated from <i>Isodon</i> species, exhibits extensive pharmacological potential; however, its mechanism of action against acute myeloid leukemia (AML) remains to be elucidated. The present study employed a combined network pharmacology and experimental approach to elucidate the anti-AML mechanisms of GLD. Potential targets were identified using database mining and a protein-protein interaction network was constructed. The Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes enrichment analyses highlighted the JAK-STAT signaling pathway as central to action by GLD. Molecular docking predicted stable binding of GLD to core targets, including STAT3. Experimental validation in HEL and K562 AML cells demonstrated that GLD potently and dose-dependently inhibits cell proliferation, with efficacy similar to the standard chemotherapeutic agent doxorubicin. Mechanistically, GLD suppressed the phosphorylation of JAK2 and STAT3. GLD also induced mitochondrial apoptosis by modulating the Bcl-2/Bax ratio and triggered G₂/M phase arrest by downregulating cyclin B1 and CDK1. These findings delineated a coherent mechanism whereby GLD exerts anti-leukemic effects by inhibiting the JAK-STAT pathway, supporting its potential as a novel lead compound for AML therapy in the future.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"31 6","pages":"267"},"PeriodicalIF":2.1,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13139818/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147841075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}